China’s NMPA approves Antengene’s XPOVIO for DLBCL

China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.

Jul 10, 2024 - 04:00

China’s NMPA approves Antengene’s XPOVIO for DLBCL

China's NMPA approved Antengene’s new indication of XPOVIO for adults with relapsed or refractory diffuse large B-cell lymphoma.

Read the original article

Tags:

Previous Article

UK pharma group reprimands Novo Nordisk for undisclosed payments

Mesoblast Resubmits BLA For Ryoncil Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Alvotech receives CRL from FDA for AVT02 BLA

Alvotech receives CRL from FDA for AVT02 BLA

Apr 14, 2023

STAT+: Apple Watch pulse oximeter feature removed to comply with ban

STAT+: Apple Watch pulse oximeter feature removed to co...

Jan 18, 2024

Stanford scientist who broke genome sequencing record on what faster diagnoses mean for patients

Stanford scientist who broke genome sequencing record o...

Mar 22, 2023